Liminatus Pharma, Inc. (LIMN) shareholders
Close on Nov 17, 2026Market cap $188.72MP/E –Yield –
Ownership
Who owns Liminatus Pharma's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chris Kim Joint filing with Valetudo Therapeutics LLC (14.30%) | 9,617,954 | 14.30% | 13D (active) amendment | Jul 2, 2026 |
| Iris Acquisition Holdings LLC | 6,900,000 | 26.50% | 13D (active) | Apr 30, 2025 |
| Ewon Comfortech Co., Ltd. | 5,500,000 | 10.90% | 13G (passive) amendment | Jun 24, 2026 |
| KH Feelux Co., Ltd | 4,000,000 | 15.40% | 13G (passive) | Apr 30, 2025 |
| Samda Biolab Co., Ltd. | 3,426,548 | 5.10% | 13G (passive) | Jul 2, 2026 |
| Nongae Apple Association 1st | 1,470,000 | 5.70% | 13G (passive) | Apr 30, 2025 |
| Red Peony Association 1st | 1,470,000 | 5.70% | 13G (passive) | Apr 30, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Chris Kim | Chief Executive Officer, Director, 10% owner | 6,169,406 | Jul 14, 2026 |
| Beom Kyu Choi | Chief Technology Officer | – | Apr 30, 2025 |
| Scott Dam | Chief Financial Officer | – | Apr 30, 2025 |
| Sang-Jin Lee | Head of Research & Development | – | Apr 30, 2025 |
| Byong Chul Yoo | Chief Science Officer | – | Apr 30, 2025 |
| II Philip Wayne Lemons | Director | – | Jul 23, 2025 |
| Richard JaiHwan Baek | Director | – | Jul 21, 2025 |
| Eun Sook Lee | Director | – | May 1, 2025 |
| Nicholas Fernandez | Director | – | Apr 30, 2025 |
| Ji Yeon Baek | Director | – | Apr 30, 2025 |
| Therapeutics LLC Valetudo | 10% owner | 5,244,351 | Jul 14, 2026 |
| Ewon Comfortech Co., Ltd. | 10% owner | 5,500,000 | Jul 6, 2026 |
| Acquisition Holdings LLC Iris | 10% owner | 6,900,000 | Aug 15, 2025 |
| KH Feelux Co., Ltd | 10% owner | 4,000,000 | Jun 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Therapeutics LLC Valetudo 10% owner | Jul 2, 2026 | Other | +3,448,926 | – | – | 5,244,351 |
| Therapeutics LLC Valetudo 10% owner | Jun 24, 2026 | Other | −4,373,603 | – | – | 1,795,803 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Liminatus Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,242 shares on Aug 26, 2026 over the last 90 days.
See a number that looks wrong?